Marshall Wace LLP Sells 24,973 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Marshall Wace LLP reduced its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 32.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 52,906 shares of the company's stock after selling 24,973 shares during the period. Marshall Wace LLP owned about 0.05% of ARS Pharmaceuticals worth $558,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Wellington Management Group LLP lifted its stake in ARS Pharmaceuticals by 0.6% in the fourth quarter. Wellington Management Group LLP now owns 163,252 shares of the company's stock worth $1,722,000 after purchasing an additional 917 shares during the last quarter. Rhumbline Advisers boosted its holdings in ARS Pharmaceuticals by 2.9% during the 4th quarter. Rhumbline Advisers now owns 65,163 shares of the company's stock valued at $687,000 after acquiring an additional 1,824 shares during the period. China Universal Asset Management Co. Ltd. grew its position in ARS Pharmaceuticals by 10.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company's stock worth $217,000 after acquiring an additional 1,962 shares during the last quarter. Mariner LLC increased its stake in ARS Pharmaceuticals by 5.8% in the 4th quarter. Mariner LLC now owns 35,908 shares of the company's stock worth $379,000 after purchasing an additional 1,972 shares during the period. Finally, LPL Financial LLC lifted its position in ARS Pharmaceuticals by 11.4% in the fourth quarter. LPL Financial LLC now owns 21,408 shares of the company's stock valued at $226,000 after purchasing an additional 2,190 shares during the last quarter. 68.16% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Laura Shawver sold 50,002 shares of the company's stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $12.30, for a total value of $615,024.60. Following the transaction, the director now owns 210,346 shares in the company, valued at approximately $2,587,255.80. This represents a 19.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Eric Karas sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the completion of the transaction, the insider now owns 7,696 shares of the company's stock, valued at approximately $107,744. The trade was a 56.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,602 shares of company stock worth $1,311,041. 40.10% of the stock is currently owned by company insiders.

ARS Pharmaceuticals Stock Down 1.4 %

Shares of NASDAQ:SPRY traded down $0.20 during trading on Monday, hitting $14.26. The stock had a trading volume of 708,124 shares, compared to its average volume of 1,178,803. ARS Pharmaceuticals, Inc. has a 12 month low of $7.55 and a 12 month high of $18.51. The company has a market capitalization of $1.40 billion, a PE ratio of -27.96 and a beta of 0.86. The firm's fifty day moving average is $12.89 and its 200 day moving average is $13.00.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last announced its earnings results on Thursday, March 20th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.56. The business had revenue of $86.58 million for the quarter, compared to the consensus estimate of $15.46 million. Equities research analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on SPRY. Raymond James raised their target price on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a "strong-buy" rating in a report on Tuesday, January 14th. William Blair reaffirmed an "outperform" rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Leerink Partners raised their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. Scotiabank assumed coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price target for the company. Finally, Oppenheimer initiated coverage on ARS Pharmaceuticals in a research report on Monday, February 10th. They issued an "outperform" rating and a $40.00 price objective on the stock. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $31.00.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.